The Patient-Centric Design award at CPHI Pharmapack 2024 went to Florida-based Dr. Ferrer BioPharma for its GentleMist nozzle for intranasal delivery devices, which was developed as part of a partnership with researchers at South Dakota State University, Bona Pharma, and the Cleveland Clinic. According to the company, “GentleMist Technology utilizes advanced fluid dynamics principles to create a gentler and more effective nasal spray. This innovative approach not only reduces discomfort but maximizes drug target delivery and optimizes droplet size distribution for improved absorption.”
Dr. Ferrer BioPharma says that 26 million nasal sprays that use the GentleMist technology have been sold in the USA, Europe and the Caribbean. In 2022, Xlear announced that it would use GentleMist nozzles in its xylitol and saline nasal spray, which is sold over the counter and online. Dr. Ferrer BioPharma’s web site lists also lists products including ClorNasal chlorpheniramine nasal spray, which is sold in Latin America for the treatment of allergies, and ClorNovir, which the company says is effective against COVID and influenza.
Read the Dr. Ferrer BioPharma press release.
